Compared to OV-mOX40L or neutralizing antibody treatment alone, the combination therapy of OV-mOX40L with anti-IL6 or anti-PD-1 antibody significantly delayed tumor growth, and the most effective tumor inhibition was observed with the triple therapy (OV-mOX40L+anti-IL6+anti-PD-1) (Figure 6B). This evidence concerns the gene PDCD1 and neoplasm.